CD19-CAR Trials
نویسندگان
چکیده
منابع مشابه
CAR therapy: the CD19 paradigm.
Twenty-five years after its inception, the genetic engineering of T cells is now a therapeutic modality pursued at an increasing number of medical centers. This immunotherapeutic strategy is predicated on gene transfer technology to instruct T lymphocytes to recognize and reject tumor cells. Chimeric antigen receptors (CARs) are synthetic receptors that mediate antigen recognition, T cell activ...
متن کاملChimeric Antigen Receptor (CAR)-Specific Monoclonal Antibody to Detect CD19-Specific T Cells in Clinical Trials
Clinical trials targeting CD19 on B-cell malignancies are underway with encouraging anti-tumor responses. Most infuse T cells genetically modified to express a chimeric antigen receptor (CAR) with specificity derived from the scFv region of a CD19-specific mouse monoclonal antibody (mAb, clone FMC63). We describe a novel anti-idiotype monoclonal antibody (mAb) to detect CD19-specific CAR(+) T c...
متن کاملApproaches to Improve Clinical Efficacy of CD19-Redirected Chimeric Antigen Receptor (CD19 CAR) T Cell Immunotherapy of Non-Hodgkin’s Lymphoma
Clinical use of CD19-redirected chimeric antigen-receptor (CD19 CAR) T cell therapy has shown promise in the treatment of various B cell malignancies including acute lymphoblastic leukemia (ALL) and non-Hodgkin’s lymphoma (NHL). However, its clinical use is limited due to inherent or acquired resistance of tumor cells to apoptotic death signals delivered by CAR transduced T cells as well as by ...
متن کاملFLAG-tagged CD19-specific CAR-T cells eliminate CD19-bearing solid tumor cells in vitro and in vivo.
Autologous T cells expressing chimeric antigen receptors (CARs) specific for CD19 have demonstrated remarkable efficacy as therapeutics for B cell malignancies. In the present study, we generated FLAG-tagged CD19-specific CAR-T cells (CD19-FLAG) and compared them to their non-tagged counterparts for their effects on solid and hematological cancer cells in vitro and in vivo. For solid tumors, we...
متن کاملIntegration of a CD19 CAR into the TCR Alpha Chain Locus Streamlines Production of Allogeneic Gene-Edited CAR T Cells
Adoptive cellular therapy using chimeric antigen receptor (CAR) T cell therapies have produced significant objective responses in patients with CD19+ hematological malignancies, including durable complete responses. Although the majority of clinical trials to date have used autologous patient cells as the starting material to generate CAR T cells, this strategy poses significant manufacturing c...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: The Cancer Journal
سال: 2014
ISSN: 1528-9117
DOI: 10.1097/ppo.0000000000000031